Latest Search
Quote
| Back Zoom + Zoom - | ||||
|
<Results>SINO BIOPHARM Interim NP Rises 12.3% to RMB3.389B; Interim DPS Adds to HKD5 Cents
Recommend 22 Positive 32 Negative 16 |
||||
|
||||
|
SINO BIOPHARM (01177.HK) announced its interim results for the six months ending June 30, 2025, reporting revenue of RMB17.575 billion, up 10.7% YoY. Net profit increased 12.3% YoY to RMB3.389 billion, with EPS at RMB18.82 cents. The company declared an interim DPS of HKD5 cents, vs HKD3 cents in the same period of last year. During the reporting period, the Group had a total of two innovative products approved for marketing by the NMPA, namely Putanning and Anqixin. In 1H25, the Group’s sales of innovative products reached RMB7.8 billion, a YoY increase of 27.2%, representing 44.4% of the Group’s revenue. It is expected that, by the end of 2027, the Group will have more than 35 marketed innovative products, with the sales of innovative products as a percentage of 60%. AAStocks Financial News |
||||
Copied to Clipboard
 |
||||
